JON NAKAMURA: Open Payments
NPI 1215059704 · LIHUE, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,017 in 42 payments from 11 companies in 2025. Trend: 2023 $521 · 2024 $1,353 · 2025 $1,017
Food & beverage: $1,017
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $212 |
| Teva Pharmaceuticals USA, Inc. | 6 | $186 |
| Alkermes, Inc. | 2 | $178 |
| Lundbeck LLC | 6 | $118 |
| Neurocrine BioSciences, Inc. | 4 | $98 |
| Axsome Therapeutics, Inc. | 4 | $92 |
| ABBVIE INC. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
Products named: TRINTELLIX, AUSTEDO XR, REXULTI, LYBALVI, INGREZZA, Auvelity, ARISTADA, VRAYLAR.
Industry payments across HI — which companies pay providers there.
